Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTAMENT OF HEALTH AND HUMAN S; INC.;BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM;AMGEN, INC.;AMGEN
发明人:
DEPAOLI ALEX M.,ALEX M. DEPAOLI,ORAL ELIF ARIOGLU,ELIF ARIOGLU ORAL,TAYLOR SIMEON I.,SIMEON I. TAYLOR,GARG ABHIMANYU,ABHIMANYU GARG
申请号：
PL374301
公开号：
PL214862B1
申请日:
2002.10.22
申请国别(地区):
PL
年份:
2013
代理人:
摘要：
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipodystrophy. Leptin is effective against lipodystrophy conditions for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including in a vector comprising nucleic acid sequences encoding leptin. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having approximately 4ng/ml or less before treatment.
